Primary Immune Cell Analysis Services for Brain Tumors

Excessive inhibition or activation of immune cells exerts a profound influence on brain tumor development. By analyzing primary immune cells isolated directly from brain tumors, researchers can access a more precise evaluation of how these cells interact with others and react to potential therapeutics. Alfa Cytology offers a comprehensive range of primary immune cell analyses customized for brain tumor research.

Primary Immune Cell Analysis in Brain Tumors

Immune cells exhibit a dual role in the development of brain tumors, where they can either promote or inhibit brain tumor growth and progression. Through the isolation and cultivation of primary immune cells in vitro, researchers can conduct a series of experiments such as immune cell activation assays and mixed lymphocyte response (MLR) tests to evaluate the function of specific immune cells and explore the underlying mechanisms of immune response during brain tumor advancement.

Fig.1 Mn²⁺ treatment upregulated PD-L1 and synergized YM101 in one-way mixed lymphocyte reaction (MLR) assay. (Yi M., et al., 2021)

Advantages of Primary Immune Cell Analysis

Performed in controlled laboratory settings, primary immune cell assays serve as valuable tools in investigating the complex interaction between immune cells and their external stimuli. They provide a more precise view of how immune cells react to potential therapeutics for brain tumors.

Our Services

Alfa Cytology offers comprehensive primary immune cell analysis services encompassing a diverse array of stimuli and various species. We aim to help our clients evaluate the in vitro efficacy of potential therapeutics by detecting immune cell proliferation, single or multiple cytokine releases and the expression of immune cell surface markers. Our primary cell analysis services are as follows.

Applicable Species and Cell Types

Specializing in the isolation of a broad spectrum of primary immune cells, our services cater to a variety of species, including monkeys, dogs, rabbits and mice. Cell types encompass PBMCs, CD3⁺ T cells, CD4⁺ T cells, CD8⁺ T cells, NK cells, Treg cells, dendritic cells, macrophages, etc.

Various Indicators

A range of parameters are thoroughly assessed to characterize the status and functionality of primary immune cells.

• Immune cell proliferation

Immune cell proliferation is crucial in tumor development as it supports effective immunosurveillance, counteracts immunosuppression within the tumor microenvironment and enhances therapeutic responses. We provide validated assays tailored to assess immune cell proliferation effectively.

• Cytokine release

The release of cytokines by immune cells is crucial for regulating immune responses. Monitoring immune cell cytokine release provides valuable insights into the immune landscape of brain tumors and guides personalized therapeutic strategies.

• Immune cell surface marker protein expression

Immune cell surface marker protein expression is crucial for immune cell subset identification and prognostic outcomes prediction. By analyzing the surface marker protein expression of immune cells, researchers are able to monitor immune responses during tumor progression and develop personalized therapeutics.

Types of Assays

Advantages of Our Primary Immune Cell Analysis

• Alfa Cytology provides primary immune cells of traceable origin to meet your filing requirements.
• Possessing successful experience in immune cell function assays for different targets, Alfa Cytology is proficient in isolating and culturing a wide range of primary cells to fulfill the requirements for evaluating different types of brain tumor therapeutics in vitro.
• Alfa Cytology offers a range of validated enzyme markers of various types, ensuring transparency and reliability in research and analysis processes.
• Our services are customizable to suit your specific requirements, ensuring timely delivery and meeting your expectations.

Contact Us

Alfa Cytology offers a diverse selection of primary immune cell activation assays and MLR assays, including customized options tailored to your requirements. Please contact our staff to learn how we can help you.

Reference

1. Yi M.; et al. (2021). Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers[J]. Journal of hematology & oncology. 14(1), 146.